## Medical encounters for TUD diagnosis in patients with T2DM and TUD (without obesity) (Comparision between matched semaglutide vs other anti-diabetes medications cohorts)

Size/cohort	Exposure	Comparison	cases (overall risk) (Exposure)	cases (overall risk) (Comparison)	RD (95% CI)		HR (95% CI)
1,302	semaglutide	insulins	238 (18.3%)	326 (25.0%)	-6.8% (-9.9%, -3.6%	)	0.60 (0.51–0.71)
1,305	semaglutide	metformin	240 (18.4%)	295 (22.6%)	-4.2% (-7.3%, -1.1%	)	0.76 (0.64–0.90)
1,283	semaglutide	DPP-4i	237 (18.5%)	289 (22.5%)	-4.1% (-7.2%, -0.9%	) ⊢■	0.77 (0.65–0.92)
1,293	semaglutide	SGLT2i	238 (18.4%)	310 (24.0%)	-5.6% (-8.7%, -2.4%	) <del></del>	0.70 (0.59–0.83)
1,292	semaglutide	SU	237 (18.3%)	297 (23.0%)	-4.6% (-7.8%, -1.5%	)	0.74 (0.62–0.88)
1,033	semaglutide	TZD	188 (18.2%)	223 (21.6%)	-3.4% (-6.8%, 0.1%)	<b>⊢</b>	0.78 (0.64–0.94)
1,268	semaglutide	other GLP-1RAs	232 (18.3%)	256 (20.2%)	-1.9% (-5.0%, 1.2%)	<b>├</b>	0.85 (0.71–1.02)
						0.30 0.40 0.60 0.801.0 Hazard Ratio (I	2.0 3.00 HR)